Date: 2016-03-15
Type of information: Private placement
Company: Clinuvel (Australia)
Investors:
Amount: A$8.3 million (€ 5.62 million)
Funding type: private placement
Planned used: These funds will be used to support the European commercial distribution of Scenesse® (afamelanotide 16mg) for patients with the rare genetic disease erythropoietic protoporphyria (EPP).
Others: * On March 15, 2016, Clinuvel Pharmaceuticals announced that the company has successfully raised A$8.3 million
dollars via a private placement to existing and new international institutional and professional investors. The placement was made at a price of A$3.30 per share, representing an issue price equal to the closing price on 10th March and a 2.9% discount to the 10th March 10-day volume weighted average price.
Therapeutic area: Ophtalmological diseases
